Alagille Syndrome Companies
Alagille syndrome is a rare genetic disorder that primarily affects the liver and heart, causing a range of symptoms such as liver damage, bile duct abnormalities, and heart problems.
Alagille syndrome is a rare genetic disorder that primarily affects the liver and heart, causing a range of symptoms such as liver damage, bile duct abnormalities, and heart problems.
Latest Alagille Syndrome Companies Updates:
CANbridge Pharma secures marketing approval for LIVMARLI in Hong Kong: This September 2023 approval marks a significant step towards broader access to the medication for patients with Alagille Syndrome in the region.
Patient advocacy groups like the Alagille Syndrome Alliance and Chiari & Associates for Alagille Syndrome (CAFAS) play a vital role in raising awareness, providing support and resources, and funding research for improved diagnosis, treatment, and cure for Alagille Syndrome.
Online communities and forums offer valuable information and connection for individuals living with Alagille Syndrome and their families.
List of Alagille Syndrome Key companies in the market:
The alagille syndrome global market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The alagille syndrome market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key players
Sanofi AG, Teva Pharmaceutical Industries Ltd., Allergen Plc, Lannett, Albireo Pharma, Inc., AstraZeneca Plc, Novartis AG, Pfizer, Inc., Shire, Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Merck & Co., Inc. are some of the key players in the global alagille syndrome market.
Regional Market Summary
Global Alagille Syndrome Market Share (%), by Region, 2017
Source: MRFR Analysis
Geographically, the Americas is anticipated to dominate the global alagille syndrome market owing to a well-developed healthcare sector, rising prevalence of rare genetic disease and growing healthcare expenditure. According to the Global Genes Project, rare and genetic diseases affect 1 in 10 people in the United States Additionally, increasing awareness among the people regarding the disease and well-developed technology is likely to contribute to the growth of the market.
Europe is expected to hold the second largest position in the alagille syndrome global market. The market growth in this region is attributed to the growing prevalence of several liver diseases, increasing prevalence of genetic disease, availability of funds for research, and increasing healthcare expenditure. According to the Public Health England, approximately 11,597 number of people died with an underlying cause of liver disease in England in 2014. In addition, according to the Office for National Statistics, gross domestic expenditure on research and development (R&D) was Euro 33.1 billion (USD 35.2 billion) in 2016.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, growing occurrences of rare diseases and increasing government funding for the healthcare sector.
On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.
Global Alagille Syndrome Market, by Symptom
Global Alagille Syndrome Market, by Treatment
Global Alagille Syndrome Market, by Diagnosis
Global Alagille Syndrome Market, by End-User
Global Alagille Syndrome Market, by Region
Intended Audience
Alagille Syndrome Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)